126 related articles for article (PubMed ID: 38385970)
1. Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database.
Lu HJ; Hsieh MC; Wang HM; Hsieh JC; Yen CJ; Wu SY; Huang HC; Wang HC; Chu PY; Chen TH; Chien CY; Huang TL; Chang YF; Hua CH; Lien MY; Chen JP; Lu WC; Lin JC; Wang CC; Liu YC; Yang MH; Lou PJ
Head Neck; 2024 May; 46(5):1063-1073. PubMed ID: 38385970
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
3. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
[TBL] [Abstract][Full Text] [Related]
4. Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.
Pitakpaiboonkul P; Jiarpinitnun C; Pattaranutaporn P; Ngamphaiboon N
Cancer Med; 2024 Feb; 13(4):e7047. PubMed ID: 38457195
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
[TBL] [Abstract][Full Text] [Related]
8. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
9. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
10. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
Wang HM; Lou PJ; Yang MH; Chen TH; Lien MY; Lin JC; Chen JP; Lu WC; Lu HJ; Huang TL; Yen CJ; Wu SY; Wang HC; Hsieh MC
Target Oncol; 2024 Jan; 19(1):51-58. PubMed ID: 38285067
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
Zech HB; Laban S; Schafhausen P; Bussmann L; Betz C; Busch CJ
HNO; 2019 Dec; 67(12):898-904. PubMed ID: 31701170
[TBL] [Abstract][Full Text] [Related]
17. Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2).
Yokota T; Ota Y; Fujii H; Kodaira T; Shimokawa M; Nakashima T; Monden N; Homma A; Ueda S; Akimoto T
Int J Clin Oncol; 2021 Feb; 26(2):316-325. PubMed ID: 33125596
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
19. Real-world Data Study of the Efficacy and Toxicity of Nivolumab
Macia-Rivas L; Fernandez-Laguna CL; Alvarez-Asteinza C; Maray I; Carbajales-Alvarez M; Lozano-Blazquez A
Anticancer Res; 2023 Apr; 43(4):1681-1688. PubMed ID: 36974777
[TBL] [Abstract][Full Text] [Related]
20. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Ng K; Metcalf R; Sacco J; Kong A; Wheeler G; Forsyth S; Bhat R; Ward J; Ensell L; Lowe H; Spanswick V; Hartley J; White L; Lloyd-Dehler E; Forster M
BMJ Open; 2023 Nov; 13(11):e070391. PubMed ID: 38011968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]